Table 3.

GMCSF-MOG prevented EAE in the midst of a CFA-induced pro-inflammatory environment

Treatment	Incidence of EAE	Mean cumulative score	Median cumulative score	Mean maximal score	Median maximal score	% maximal weight loss
(a) MOG/CFA + GMCSF-PLP	6 of 6	40.8 ± 15.1	43.3	3.1 ± 0.7	3.0	17.2%
(b) MOG/CFA + GMCSF-MOG	2 of 6	4.0 ± 8.4	0.0	0.8 ± 1.3	0.0	3.4%
(c) MOG/CFA alone + saline	8 of 8	56.6 ± 18.3	54.5	3.7 ± 0.5	4.0	19.0%
(d) PBS/CFA + GMCSF-MOG	0 of 6	0.0 ± 0.0	0.0	0.0 ± 0.0	0.0	1.7%

(a–d) C57BL/6 mice were injected with 77.5 nmole (200 μg) MOG35-55 in CFA with an adjacent injection of saline (c) or 2 nmole of either GMCSF-PLP (a) or GMCSF-MOG (b) in saline. A separate group of mice were injected with a saline/CFA emulsion and an adjacent injection of 2 nmole GMCSF-MOG (d). All four groups also received Pertussis toxin (200 ng i.p.) on days 0 and 2. Data analysis was based on daily assessments from day 0 to day 35. These data were previously shown as a density dot plot (Figure 6B of (14)).(b) and (d) versus (a) or (c); cumulative score, p < 0.001, maximal score, p≤0.002, maximal weight loss, p≤0.004.